The Importance of Multidisciplinary Collaboration With Subspecialty Physicians in the Toxicity Management With Treatment

EP: 1.The Evolution of EGFR-Mutated Advanced NSCLC Treatment: Present Considerations and Future Treatment Options

EP: 2.Has Combination Therapy Become the New Frontline Treatment Standard for EGFR-Mutant Metastatic NSCLC?

EP: 3.Decision Points to Consider When Choosing Treatment With Monotherapy or Combination Therapy for EGFR-Mutant mNSCLC

EP: 4.Evaluating Patient Preferences for the Treatment of EGFR-Mutant mNSCLC

EP: 5.Comparing the Combination Therapies for the Treatment of EGFR-Mutant mNSCLC

EP: 6.Considering Resistance Mechanisms When Choosing Therapy in the Frontline Setting

EP: 7.The Importance of Maintaining Quality of Life and Intervening Early When Adverse Events Occur in the Frontline Treatment Setting

EP: 8.Weighing the 1-Year Projected Overall Survival Benefit With MARIPOSA in the Frontline Treatment of EGFR-Mutant mNSCLC

EP: 9.Discussing the Time and Financial Toxicities Associated With Combination Therapies and Potential Mitigation Strategies

EP: 10.Discussing Potential Combination Therapy Medication-Associated Toxicities With Patients

EP: 11.Evaluating the Clinical Utility of Subcutaneous Amivantamab in the Treatment of EGFR-Mutant mNSCLC

Now Viewing

EP: 12.The Importance of Multidisciplinary Collaboration With Subspecialty Physicians in the Toxicity Management With Treatment

EP: 13.Exploring Second-Line Treatment Options Including Targeted Radiation and Surgery for the Management of EGFR-Mutant mNSCLC

EP: 14.Tissue vs Plasma Biopsy After First Disease Progression in EGFR-Mutant NSCLC

EP: 15.Deciding Between a Biomarker-Directed Approach and a Biomarker-Agnostic Approach for Second-Line Treatment of EGFR-Mutant NSCLC

EP: 16.Continuing the Targeted TKI in the Second Line for the Treatment of EGFR-Mutant NSCLC

EP: 17.When to Consider Retreatment With Chemotherapy After FLAURA2 for EGFR-Mutant NSCLC

EP: 18.Patient Case Presentation: A 45-Year-Old With Newly Diagnosed EGFR-Mutant mNSCLC and Liver Metastases

EP: 19.Patient Case Presentation: A 69-Year-Old With Newly Diagnosed EGFR-Mutant mNSCLC and Symptomatic Brain Metastases

This segment emphasizes the critical importance of multidisciplinary collaboration with subspecialty physicians, particularly dermatologists, for managing treatment-related toxicities associated with combination therapies for EGFR-mutant metastatic non–small cell lung cancer. The discussion highlights how dermatologists, even those practicing in community settings, have become increasingly familiar with oncology-related skin toxicities, particularly since the widespread adoption of immunotherapy. While these specialists may not be familiar with specific oncologic drugs, they have developed expertise in managing the resulting toxicities, which is essential when standard prophylactic measures fail to control treatment-related adverse effects.

The evolution of subspecialty support reflects the growing complexity of modern cancer treatment. As novel therapies like amivantamab and tyrosine kinase inhibitors become more ubiquitous, subspecialists across various disciplines have adapted to handle previously unfamiliar toxicities. This adaptation process mirrors what occurred with immunotherapy-related adverse events, where specialists learned to manage complications they had not previously encountered. The initial management typically occurs under oncology guidance, but as these toxicities become more common, subspecialists develop independent expertise in their management, creating a more robust support network for patients experiencing treatment-related complications.

Geographic proximity to academic medical centers provides significant advantages for toxicity management, offering access not only to second opinions from oncologists but also to highly specialized subspecialists who have developed expertise through collaboration with oncology departments. These academic-affiliated specialists often serve as local experts, becoming the preferred referral destinations for managing specific toxicities. This network of subspecialty support is particularly valuable for complex cases where standard interventions prove inadequate. The availability of experienced subspecialists who understand the unique challenges of oncology-related toxicities ensures that patients can receive comprehensive care that addresses both cancer treatment efficacy and quality of life preservation through effective adverse event management.